ArticleStem cell reviews and reports2026
Bulge Progenitor Cells: A Promising Frontier in Hair Follicle Regeneration and Clinical Translation.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
highlight• Bulge progenitors' cells (BPC) are multipotent cells that fuel hair follicle cycling, sebaceous turnover, and epidermal repair.• BPC activation from quiescence is governed by niche-derived Wnt/β-catenin (anagen entry), BMP antagonism (licensing transit), and TGF-β/Smad (catagen enforcement).• Preclinical models demonstrate de novo folliculogenesis using BPC- dermal papilla cell recombinants in 3D scaffolds, with > 70% graft viability and restored cyclic hair growth.• Early-phase clinical trials of autologous BPC-enriched micrografts report 20-30% increases in hair density in androgenetic alopecia, with minimal adverse events.• Translational realization demands GMP-compliant isolation, biomimetic niche engineering (hydrogels, bioprinting), and immunomodulatory strategies to ensure safety, scalability, and durability.
Indexed as
Identifiers
42698034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.